Health Care [ 6/12 ] | Biotechnology [ 45/74 ]
NASDAQ | Common Stock
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases.
It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.
IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies.
The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010.
IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 24 | -0.79 Increased by +44.76% | -0.04 Decreased by -1.88 K% |
| May 8, 24 | -0.83 Increased by +37.59% | -0.83 |
| Mar 7, 24 | -1.01 Increased by +15.13% | -1.03 Increased by +1.94% |
| Nov 13, 23 | -1.04 Increased by +21.21% | -1.21 Increased by +14.05% |
| Aug 3, 23 | -1.43 Decreased by -7.52% | -1.43 |
| May 12, 23 | -1.33 Increased by +13.07% | -1.36 Increased by +2.21% |
| Mar 30, 23 | -1.19 Increased by +20.67% | -1.25 Increased by +4.80% |
| Nov 3, 22 | -1.32 Increased by 0.00% | -1.43 Increased by +7.69% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 1.25 M Increased by +179.91% | -47.90 M Increased by +25.64% | Decreased by -3.82 K% Increased by +73.44% |
| Mar 31, 24 | 497.00 K Decreased by -4.79% | -49.82 M Increased by +16.01% | Decreased by -10.02 K% Increased by +11.78% |
| Dec 31, 23 | 651.00 K Increased by +75.00% | -60.70 M Decreased by -25.93% | Decreased by -9.32 K% Increased by +28.04% |
| Sep 30, 23 | 509.00 K Increased by +53.78% | -61.99 M Decreased by -11.57% | Decreased by -12.18 K% Increased by +27.45% |
| Jun 30, 23 | 448.00 K Increased by +22.40% | -64.42 M Decreased by -11.14% | Decreased by -14.38 K% Increased by +9.20% |
| Mar 31, 23 | 522.00 K Increased by +N/A% | -59.31 M Decreased by -14.43% | Decreased by -11.36 K% Decreased by N/A% |
| Dec 31, 22 | 372.00 K Increased by +N/A% | -48.20 M Increased by +4.83% | Decreased by -12.96 K% Decreased by N/A% |
| Sep 30, 22 | 331.00 K Increased by +N/A% | -55.56 M Decreased by -25.81% | Decreased by -16.79 K% Decreased by N/A% |